Dermapharm Holding SE (ETR: DMP)

Dermapharm Holding SE Statistics

Total Valuation

Dermapharm Holding SE has a market cap or net worth of EUR 2.05 billion. The enterprise value is 2.96 billion.

Market Cap	2.05B
Enterprise Value	2.96B

Important Dates

The next estimated earnings date is Friday, March 28, 2025.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	Jun 28, 2024

Share Statistics

Dermapharm Holding SE has 53.84 million shares outstanding. The number of shares has increased by 0.23% in one year.

Current Share Class	n/a
Shares Outstanding	53.84M
Shares Change (YoY)	+0.23%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	16.91%
Float	10.50M

Valuation Ratios

The trailing PE ratio is 22.63 and the forward PE ratio is 16.82. Dermapharm Holding SE's PEG ratio is 0.55.

PE Ratio	22.63
Forward PE	16.82
PS Ratio	1.75
PB Ratio	3.51
P/TBV Ratio	n/a
P/FCF Ratio	13.02
P/OCF Ratio	n/a
PEG Ratio	0.55

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.22, with an EV/FCF ratio of 18.83.

EV / Earnings	32.66
EV / Sales	2.52
EV / EBITDA	12.22
EV / EBIT	13.73
EV / FCF	18.83

Financial Position

The company has a current ratio of 1.66, with a Debt / Equity ratio of 1.74.

Current Ratio	1.66
Quick Ratio	0.65
Debt / Equity	1.74
Debt / EBITDA	4.26
Debt / FCF	6.53
Interest Coverage	3.70

Financial Efficiency

Return on equity (ROE) is 15.75% and return on invested capital (ROIC) is 8.23%.

Return on Equity (ROE)	15.75%
Return on Assets (ROA)	6.26%
Return on Capital (ROIC)	8.23%
Revenue Per Employee	335,696
Profits Per Employee	25,904
Employee Count	3,497
Asset Turnover	0.55
Inventory Turnover	1.29

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -8.27% in the last 52 weeks. The beta is 1.11, so Dermapharm Holding SE's price volatility has been higher than the market average.

Beta (5Y)	1.11
52-Week Price Change	-8.27%
50-Day Moving Average	34.41
200-Day Moving Average	34.67
Relative Strength Index (RSI)	63.64
Average Volume (20 Days)	47,842

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Dermapharm Holding SE had revenue of EUR 1.17 billion and earned 90.59 million in profits. Earnings per share was 1.68.

Revenue	1.17B
Gross Profit	734.32M
Operating Income	214.41M
Pretax Income	141.76M
Net Income	90.59M
EBITDA	234.73M
EBIT	214.41M
Earnings Per Share (EPS)	1.68

Balance Sheet

The company has 118.57 million in cash and 1.03 billion in debt, giving a net cash position of -906.93 million or -16.84 per share.

Cash & Cash Equivalents	118.57M
Total Debt	1.03B
Net Cash	-906.93M
Net Cash Per Share	-16.84
Equity (Book Value)	589.04M
Book Value Per Share	10.81
Working Capital	248.17M

Cash Flow

In the last 12 months, operating cash flow was 196.76 million and capital expenditures -39.66 million, giving a free cash flow of 157.10 million.

Operating Cash Flow	196.76M
Capital Expenditures	-39.66M
Free Cash Flow	157.10M
FCF Per Share	2.92

Margins

Gross margin is 62.55%, with operating and profit margins of 18.26% and 7.72%.

Gross Margin	62.55%
Operating Margin	18.26%
Pretax Margin	12.08%
Profit Margin	7.72%
EBITDA Margin	19.99%
EBIT Margin	18.26%
FCF Margin	13.38%

Dividends & Yields

This stock pays an annual dividend of 0.88, which amounts to a dividend yield of 2.32%.

Dividend Per Share	0.88
Dividend Yield	2.32%
Dividend Growth (YoY)	-16.19%
Years of Dividend Growth	n/a
Payout Ratio	52.30%
Buyback Yield	-0.23%
Shareholder Yield	2.09%
Earnings Yield	4.42%
FCF Yield	7.68%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Dermapharm Holding SE has an Altman Z-Score of 2.07. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.07
Piotroski F-Score	n/a